Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Susanna W.L. de Geus

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8995-2304; OpenAlex author ID A5014584070, A5065159677. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2016: 4 papers · 2017: 5 papers · 2018: 3 papers · 2019: 2 papers · 2020: none · 2021: none · 2022: 1 paper · 2023: 2 papers

Papers 17

  1. The Evaluation of Gallstone Disease in the Year Before Pancreatic Cancer Diagnosis. First author DOI 10.1016/j.jss.2023.06.017↗
  2. A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-023-13281-1↗
  3. The impact of upper gastrointestinal surgical volume on short term pancreaticoduodenectomy outcomes for pancreatic adenocarcinoma in the SEER-Medicare populati… First author DOI 10.1016/j.hpb.2021.10.015↗
  4. Impact of Race, Insurance Status, and Primary Language on Presentation, Treatment, and Outcomes of Patients with Pancreatic Adenocarcinoma at a Safety-Net Hosp… Co-author DOI 10.1016/j.jamcollsurg.2019.05.027↗
  5. ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer. Co-author DOI 10.1126/sciadv.aax2770↗
  6. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2018.3617↗
  7. Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study. Co-author DOI 10.1007/s11605-017-3541-8↗
  8. Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2017.12.004↗
  9. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. Co-author DOI 10.1002/cncr.30856↗
  10. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis. Co-author DOI 10.1016/j.surg.2016.08.040↗
  11. Evolution and impact of lymph node dissection during pancreaticoduodenectomy for pancreatic cancer. First author DOI 10.1016/j.surg.2016.09.032↗
  12. Regional variation in the treatment of pancreatic adenocarcinoma: Decreasing disparities with multimodality therapy. Co-author DOI 10.1016/j.surg.2017.03.009↗
  13. Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells. Co-author DOI 10.1177/1177271917715443↗
  14. Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery. Co-author DOI 10.1007/s11307-016-0959-4↗
  15. A Tale of Two Cities: Reconsidering Adjuvant Radiation in Pancreatic Cancer Care. Co-author DOI 10.1007/s11605-015-2951-8↗
  16. Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis. Co-author DOI 10.1016/j.ejso.2016.07.016↗
  17. Early surgical bypass versus endoscopic stent placement in pancreatic cancer. Co-author DOI 10.1016/j.hpb.2016.05.008↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jennifer F. Tseng · 13 shared papers, 2016–2023 · strength 1.14
  2. Teviah Erik Sachs · 5 shared papers, 2018–2023 · strength 0.92
  3. Mariam F. Eskander · 8 shared papers, 2016–2018 · strength 0.54
  4. Gyulnara G. Kasumova · 7 shared papers, 2017–2018 · strength 0.52
  5. Mark P. Callery · 6 shared papers, 2016–2018 · strength 0.42
  6. Alexander L. Vahrmeijer · 6 shared papers, 2016–2019 · strength 0.42
  7. Tara Sotsky Kent · 6 shared papers, 2016–2018 · strength 0.41
  8. Marianna V. Papageorge · 2 shared papers, 2022–2023 · strength 0.36
  9. Arthur James Moser · 4 shared papers, 2016–2018 · strength 0.28
  10. Lindsay A. Bliss · 4 shared papers, 2016–2017 · strength 0.25
  11. Peter J.K. Kuppen · 3 shared papers, 2016–2019 · strength 0.20
  12. Cornelis F.M. Sier · 3 shared papers, 2016–2019 · strength 0.20
  13. Anand Mahadevan · 3 shared papers, 2016–2017 · strength 0.19
  14. Bert A. Bonsing · 3 shared papers, 2016–2017 · strength 0.17
  15. Rebecca Anne Miksad · 2 shared papers, 2016–2017 · strength 0.13
  16. Hans Morreau · 2 shared papers, 2016–2017 · strength 0.12
  17. Praveen Sridhar · 1 shared paper, 2019 · strength 0.10
  18. Jonas Schnittert · 1 shared paper, 2019 · strength 0.08
  19. Praneeth Reddy Kuninty · 1 shared paper, 2019 · strength 0.08
  20. Deby Fajar Mardhian · 1 shared paper, 2019 · strength 0.08
  21. Hanneke W.M. van Laarhoven · 1 shared paper, 2019 · strength 0.08
  22. Arne Östman · 1 shared paper, 2019 · strength 0.08
  23. Jai Prakash · 1 shared paper, 2019 · strength 0.08
  24. Maarten F. Bijlsma · 1 shared paper, 2019 · strength 0.08
  25. Joseph Douglas Mancias · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.